Sirolimus for the treatment of juvenile nasopharyngeal angiofibroma
- 11 January 2020
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (4) , e28162
Abstract
Juvenile nasopharyngeal angiofibroma (JNA) is a pathologically benign yet locally aggressive and destructive tumor that develops in the choana and nasopharynx. Historical treatment of JNA has included embolization, surgical resection, and radiation. Here, we describe three patients who received therapy with the mTOR inhibitor sirolimus with improvement in clinical symptoms, imaging, and overall well‐being.Keywords
This publication has 25 references indexed in Scilit:
- Juvenile Angiofibroma: Evolution of ManagementInternational Journal of Pediatrics, 2011
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Mammalian Target of Rapamycin (mTOR) is Activated in Cutaneous Vascular Malformations in VivoLymphatic Research and Biology, 2007
- MANAGEMENT OF INVASIVE JUVENILE NASOPHARYNGEAL ANGIOFIBROMASNeurosurgery, 2007
- mTOR-targeted therapy of cancer with rapamycin derivativesAnnals of Oncology, 2005
- Dysregulation of the TSC-mTOR pathway in human diseaseNature Genetics, 2004
- Nasopharyngeal Angiofibroma: True Neoplasm or Vascular Malformation?Advances in Anatomic Pathology, 2000
- Juvenile nasopharyngeal angiofibroma contain an angiogenic growth factor: Basic FGFThe Laryngoscope, 1992
- Malignant transformation of a nasopharyngeal angiofibromaThe Laryngoscope, 1989
- JUVENILE NASOPHARYNGEAL ANGIOFIBROMAAnnals of Surgery, 1948